HK1044486A1 - 使用性激素來獲得可用於治療不合需要的子宮出血的鼻腔藥物組合物 - Google Patents

使用性激素來獲得可用於治療不合需要的子宮出血的鼻腔藥物組合物

Info

Publication number
HK1044486A1
HK1044486A1 HK02106208.3A HK02106208A HK1044486A1 HK 1044486 A1 HK1044486 A1 HK 1044486A1 HK 02106208 A HK02106208 A HK 02106208A HK 1044486 A1 HK1044486 A1 HK 1044486A1
Authority
HK
Hong Kong
Prior art keywords
useful
treatment
pharmaceutical composition
uterine bleeding
sex hormones
Prior art date
Application number
HK02106208.3A
Other languages
English (en)
Inventor
Y‧楚德羅斯
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab filed Critical Servier Lab
Publication of HK1044486A1 publication Critical patent/HK1044486A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Otolaryngology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
HK02106208.3A 1999-03-31 2002-08-23 使用性激素來獲得可用於治療不合需要的子宮出血的鼻腔藥物組合物 HK1044486A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9904022A FR2791572A1 (fr) 1999-03-31 1999-03-31 Utilisation d'hormones sexuelles pour l'obtention d'une composition pharmaceutique nasale utile pour le traitement des saignements uterins indesirables
PCT/FR2000/000790 WO2000059447A2 (fr) 1999-03-31 2000-03-30 Utilisation d'hormones sexuelles pour l'obtention d'une composition pharmaceutique nasale utile pour le traitement des saignements uterins indesirables

Publications (1)

Publication Number Publication Date
HK1044486A1 true HK1044486A1 (zh) 2002-10-25

Family

ID=9543854

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02106208.3A HK1044486A1 (zh) 1999-03-31 2002-08-23 使用性激素來獲得可用於治療不合需要的子宮出血的鼻腔藥物組合物

Country Status (16)

Country Link
EP (1) EP1143978A2 (zh)
JP (1) JP2002541076A (zh)
KR (1) KR20010102464A (zh)
CN (1) CN1346273A (zh)
AU (1) AU3662300A (zh)
BR (1) BR0008577A (zh)
CA (1) CA2361885A1 (zh)
EA (1) EA200100801A1 (zh)
FR (1) FR2791572A1 (zh)
HK (1) HK1044486A1 (zh)
HU (1) HUP0200244A3 (zh)
NO (1) NO20014022D0 (zh)
NZ (1) NZ513672A (zh)
PL (1) PL356767A1 (zh)
WO (1) WO2000059447A2 (zh)
ZA (1) ZA200106689B (zh)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4383993A (en) * 1980-05-30 1983-05-17 University Of Kentucky Research Foundation Nasal dosage forms containing natural female sex hormones
NL8801670A (nl) * 1988-07-01 1990-02-01 Walter Adrianus Josephus Johan Farmaceutisch preparaat.
US5922699A (en) * 1996-06-07 1999-07-13 Pherin Corporation 19-nor-cholane steroids as neurochemical initiators of change in human hypothalamic function
EP0914165B1 (en) * 1996-07-23 2006-10-18 Pherin Pharmaceuticals, Inc. Steroids as neurochemical stimulators of the vno to alleviate symptoms of pms

Also Published As

Publication number Publication date
EA200100801A1 (ru) 2002-04-25
JP2002541076A (ja) 2002-12-03
WO2000059447A3 (fr) 2001-04-26
AU3662300A (en) 2000-10-23
EP1143978A2 (fr) 2001-10-17
ZA200106689B (en) 2002-11-14
KR20010102464A (ko) 2001-11-15
NO20014022L (no) 2001-08-17
FR2791572A1 (fr) 2000-10-06
CN1346273A (zh) 2002-04-24
HUP0200244A2 (hu) 2002-07-29
HUP0200244A3 (en) 2003-05-28
PL356767A1 (en) 2004-07-12
WO2000059447A2 (fr) 2000-10-12
NZ513672A (en) 2001-09-28
NO20014022D0 (no) 2001-08-17
CA2361885A1 (fr) 2000-10-12
BR0008577A (pt) 2002-10-01

Similar Documents

Publication Publication Date Title
HUP0103494A2 (en) Process for intermittent administration use of growth hormone secretagogues for the manufacture of pharmaceutical compositions for intermittent administration and kit comprising thereof
HUP0102899A3 (en) Process for preparation of compositions for the application of anti-inflammatory, especially antiseptic agents and/or agents promoting the healing of wounds, to the lower respiratory tract
AU8270701A (en) Improvements in and relating to the use of honey in dressings
HUP0301212A3 (en) Use of glucagon-like peptide-1 analogs for preparation pharmaceutical compositions and for treating diabetes
GB0009469D0 (en) Improvements in or relating to formalities for use in inhaler devices
HK1005985A1 (en) Combined use of hyaluronic acid and therapeutic agents to improve the therapeutic effect
HU0103558D0 (en) Pharmaceutical composition for the treatment of stroke and traumatic brain insury
HUP0204574A3 (en) Propionic acid derivatives and their use in the treatment of diabetes and obesity, pharmaceutical compositions containing them and their preparation
EP1404343A4 (en) THERAPEUTIC COMBINATIONS FOR THE TREATMENT OF HORMONE DEFICIENCIES
MY136952A (en) Aqueous sustained-release formulations of proteins
GB0013378D0 (en) Use of therapeutic benzamide derivatives
HK1149719A1 (en) Ciclesonide contained pharmaceutical composition for application to mucosa
HUP0301244A3 (en) Use of rapamycin for preparation of pharmaceutical composition to treat heart and cardiovascular diseases
HUP0301460A3 (en) Use of antiprogestins for producing pharmaceutical compositions for prohylaxis and treatment of hormone-dependent diseases
AU2073502A (en) Substituted derivatives of aminofuran-2-yl-acetic acid and aminothien-2-yl-acetic acid and the use thereof for treating migraines and pain
AU6788701A (en) Medicinal components comprising human parathyroid hormone and medicinal compositions for nasal administration containing the components
GB9912639D0 (en) Improvements in and relating to treatment of respiratory conditions
NZ513672A (en) Use of sex hormones to obtain a nasal pharmaceutical composition that is useful in the treatment of undesirable uterine bleeding
GB0026923D0 (en) Veterinary composition for the topical treatment of traumatized or inflamed skin
HUP0102696A3 (en) Use of growth hormone secretagogues for the preparation of pharmaceutical compositions stimulating or increasing appetite
IL150122A0 (en) Remedies for external use for allergic skin diseases
AU6985900A (en) Use of n-acetyl-cysteine in the manufacture of topical pharmaceutical compositions for the treatment of allergic pathologies of the respiratory tract
PL352314A1 (en) Use of 15-deoxyspergualine for treatment of hyperreactive inflammatory diseases and autoimmunization diseases
ZA981729B (en) Use of pivagabin to prepare pharmaceutical compositions
HUP0201875A2 (en) Use of antiprogestagens for preparing pharmaceutical compositions for contraception in combined therapy